Piper Sandler analyst Yasmeen Rahimi downgraded Soleno Therapeutics (SLNO) to Neutral from Overweight with a price target of $53, down from $145, after Neurocrine (NBIX) announced a deal to acquire the company for $2.9B or $53 per share in cash.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO: